Results 121 to 130 of about 7,787,676 (175)

HPV‐Related Cancers in Solid Organ Transplant Recipients: A Nationwide Danish Cohort Study

International Journal of Cancer, Volume 159, Issue 6, Page 1432-1439, 15 September 2026.
Solid organ transplant recipients (SOTRs) face chronic immunosuppression, leaving them susceptible to viral infections. Of particular concern is persistent infection with human papillomavirus (HPV), which presents a significant cancer risk. This nationwide Danish cohort study estimated cancer risk in SOTRs using health registry data.
Signe Timm, Flemming Skjøth, Torben Frøstrup Hansen, Lars Henrik Jensen, Paw Christian Holdgaard, Lars Ulrik Fokdal, Torben Bjerregaard Larsen, Mette Moeller Soerensen   +7 more
wiley   +1 more source

Response to LTE: Clinical Considerations on HPV Knowledge, Screening, and Vaccination in Brazilian Primary Care

Health Science Reports, Volume 9, Issue 10, October 2026.
Alessandra Monteiro Ramos, Cláudia Vicari Bolignani, Leila Bernarda Donato Göttems, Ana Maria Costa, Heleno Rodrigues Corrêa Filho, Wania Maria do Espírito Santo Carvalho, Fábio Ferreira Amorim   +6 more
wiley   +1 more source

Human Papillomavirus Vaccine: A New Opportunity for The Treatment of Human Papillomavirus Infections

National Journal of Community Medicine, 2014
...
Sneha Ambwani, Prabhu Prakash, Seema Surana, Suman Bhansali   +3 more
doaj  

The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination

The human papillomavirus (HPV) vaccine was initially approved for a three-dose regimen. Due to resource limitations, budget constraints, low acceptance, and poor adherence, global vaccination coverage is only 15%.
Zhengyu Li, Yue Huang, Rongyu Liu, Wanying Bao, Xinlin He   +4 more
core   +1 more source

Effectiveness of an educational intervention in enhancing parents' knowledge, perception, and acceptability of human papillomavirus vaccine. [PDF]

BMC Public Health
Abdulghani N, Faqih S, Alqurashi A, Baljon K.   +3 more
europepmc   +1 more source

Quality Improvement Partnership to Improve Human Papillomavirus Vaccine Rates: Start at Age 9 Campaign. [PDF]

Pediatr Qual Saf
Ng LE, Fenton JP, Mermelstein L, Ellis L, Trope R.   +4 more
europepmc   +1 more source

Vaccine [PDF]

BackgroundTo investigate concerns about a potential association between quadrivalent human papillomavirus vaccination (HPV4) and venous thromboembolism (VTE), we conducted a self-controlled case series study in adolescents and young adults 9\u201326 ...

core  

Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial

Background: Prophylactic human papillomavirus (HPV) vaccination substantially alleviates cervical cancer burden. This study aimed to evaluate the safety, tolerability, and immunogenicity of an Escherichia coli-expressed recombinant nonavalent HPV vaccine.
Mingwei Wei, Weiwei Han, Yongjiang Liu, Jingxin Li, Jing Zhang, Hongyang Yu, Wenjuan Wang   +6 more
core   +1 more source

Association of Guillain-Barré Syndrome With Nonavalent Human Papillomavirus Vaccine: A Postmarketing Drug Safety Study. [PDF]

Obstet Gynecol Int
González Mariño MA.
europepmc   +1 more source

Comment on Almutairi <i>et al</i>.-Understanding the boundaries of Human papillomavirus vaccine protection. [PDF]

J Family Med Prim Care
Sakore J, Ray S.
europepmc   +1 more source